PFIZER INC's ticker is PFE and the CUSIP is 717081103. A total of 2,825 filers reported holding PFIZER INC in Q1 2024. The put-call ratio across all filers is 1.67 and the average weighting 0.3%.
About PFIZER INC
Pfizer Inc. is a global pharmaceutical company that has been in operation for over 170 years. The company is headquartered in New York City and has a presence in over 150 countries worldwide. Pfizer is known for its innovative research and development of drugs that have helped to improve the lives of millions of people around the world.
One of Pfizer's most well-known products is Viagra, a drug used to treat erectile dysfunction. However, the company has a much broader portfolio of products that includes treatments for cancer, cardiovascular disease, and rare diseases. Pfizer has also been at the forefront of the fight against COVID-19, developing a vaccine that has been authorized for emergency use in many countries.
Pfizer's success can be attributed to its commitment to research and development. The company invests heavily in R&D, with over $8 billion spent in 2020 alone. This investment has led to the development of many groundbreaking drugs, including Lipitor, the best-selling drug of all time.
Despite its success, Pfizer faces challenges in the form of competition from other pharmaceutical companies and the ongoing COVID-19 pandemic. However, the company's strong financial position and commitment to innovation make it well-positioned to continue to thrive in the years to come.
In conclusion, Pfizer Inc. is a global pharmaceutical company that has been at the forefront of drug development for over 170 years. The company's commitment to research and development has led to the development of many groundbreaking drugs, and its recent success in the fight against COVID-19 has further cemented its position as a leader in the industry.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,273,562 | +8.9% | 45,517 | +8.0% | 0.68% | +3.6% |
| Q1 2024 | $1,169,512 | +6.4% | 42,145 | +10.4% | 0.66% | +1.2% |
| Q4 2023 | $1,098,858 | +15.9% | 38,168 | +33.5% | 0.65% | +5.5% |
| Q3 2023 | $948,514 | +178.6% | 28,596 | +208.1% | 0.62% | +176.3% |
| Q2 2023 | $340,447 | -74.8% | 9,282 | -72.0% | 0.22% | -71.8% |
| Q1 2023 | $1,352,520 | -9.7% | 33,150 | +13.4% | 0.79% | -16.9% |
| Q4 2022 | $1,498,463 | +52.7% | 29,244 | +30.5% | 0.96% | +39.8% |
| Q3 2022 | $981,000 | -18.0% | 22,415 | -1.8% | 0.68% | -12.8% |
| Q2 2022 | $1,197,000 | +10.1% | 22,828 | +8.8% | 0.78% | +24.8% |
| Q1 2022 | $1,087,000 | +33.5% | 20,988 | +52.3% | 0.63% | +43.4% |
| Q4 2021 | $814,000 | +69.6% | 13,782 | +12.4% | 0.44% | +27.7% |
| Q2 2021 | $480,000 | +11.1% | 12,266 | +2.8% | 0.34% | -1.7% |
| Q1 2021 | $432,000 | +0.9% | 11,934 | -2.6% | 0.35% | +79.9% |
| Q4 2020 | $428,000 | – | 12,248 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GAVEA INVESTIMENTOS LTDA | 152,208 | $5,586,000 | 13.34% |
| Northeast Financial Consultants Inc | 2,831,571 | $103,918,000 | 9.39% |
| HORIZON BANCORP INC /IN/ | 137,121 | $5,032,000 | 7.13% |
| Game Creek Capital, LP | 251,250 | $9,221,000 | 6.93% |
| CINCINNATI CASUALTY CO | 236,400 | $8,676,000 | 6.77% |
| OAKVIEW CAPITAL MANAGEMENT, L.P. | 383,240 | $14,065,000 | 6.14% |
| H2O AM LLP | 90,852 | $3,334,000 | 5.45% |
| EDGAR LOMAX CO/VA | 1,849,112 | $67,862,000 | 5.23% |
| Eliot Finkel Investment Counsel, LLC | 149,366 | $5,482,000 | 4.88% |
| KAHN BROTHERS GROUP INC | 692,544 | $25,416,366,000 | 4.82% |